Zealand, Boehringer receive FDA breakthrough status for treatment of fatty liver dystrophy

Danish Zealand Pharma and German partner Boehringer Ingelheim have won the US Food and Drug Administration’s Breakthrough Therapy competition to review their experimental weight-loss drug for the treatment of fatty liver disease.

Teile diesen Beitrag:

BELIEBTE BEITRÄGE
FOLGEN SIE UNS
Like uns auf Facebook
Folge uns auf Twitter
Abonniere unseren Kanal
Tick Tack
LIVEÜBERTRAGUNG